Interaction of topoisomerase II-targeted anticancer agents with the doxorubicin cardioprotective drug dexrazoxane, and synthesis of a dexrazoxane analog
| dc.contributor.author | Tran, Khanh Tuan | en_US |
| dc.date.accessioned | 2007-05-22T15:17:11Z | |
| dc.date.available | 2007-05-22T15:17:11Z | |
| dc.date.issued | 1999-04-01T00:00:00Z | en_US |
| dc.degree.discipline | Pharmacy | en_US |
| dc.degree.level | Master of Science (M.Sc.) | en_US |
| dc.description.abstract | The anthrapyrazoles losoxantrone and piroxantrone are topoisomerase II-targeted anticancer agents that were developed as alternatives to anthracycline anticancer drugs, such as doxorubicin to prevent cardiotoxicity. In this study the formation of the Fe$\sp{3+}$ complexes of lo oxantrone and piroxantrone, and the dissociation of the complexes in the presence of dexrazoxane (ICRF-187, Zinecard$\sp\circler,$ Cardioxane$\sp\circler),$ and its hydrolyzed form ADR-925 were investigated spectrophotometrically. Both losoxantrone and piroxantrone were shown to chelate to Fe$\sp{3+}.$ These Fe$\sp{3+}$-drug complexes were shown to be dissociated in the presence of dexrazoxane and ADR-925. The Fe$\sp{3+}$-drug complex formation could be the cause of the observed cardiotoxic side effects induced by losoxantrone and piroxantrone in previous animal and clinical studies. The Fe$\sp{3+}$-drug dissociation could provide a way to minimize the cardiotoxicity when dexrazoxane and either losoxantrone or piroxantrone are used together. The antagonistic effects of dexrazoxane and topoisomerase II-targeted anticancer agents, such as m-amsacrine, etoposide, teniposide, losoxantrone, and piroxantrone were studied using Chinese hamster ovary cells. The above topoisomerase II-targeted anticancer agents were found to antagonize dexrazoxane at different concentrations. In order to improve the cardioprotective effect of dexrazoxane, an analog bisdioxopiperidine 1 was synthesized. The rate of the hydrolysis of compound 1 was found to be two times slower than that of dexrazoxane at 37$\sp\circ$C and pH 7.4. The hydrolyzed form of compound 1 was not a good Fe$\sp{3+}$ chelator compared to the hydrolyzed form of dexrazoxane, ADR-925. | en_US |
| dc.format.extent | 6635773 bytes | |
| dc.format.extent | 184 bytes | |
| dc.format.mimetype | application/pdf | |
| dc.format.mimetype | text/plain | |
| dc.identifier.uri | http://hdl.handle.net/1993/2118 | |
| dc.language.iso | eng | en_US |
| dc.rights | open access | en_US |
| dc.title | Interaction of topoisomerase II-targeted anticancer agents with the doxorubicin cardioprotective drug dexrazoxane, and synthesis of a dexrazoxane analog | en_US |
| dc.type | master thesis | en_US |